IL97932A - Proteins and polypeptides having substituted cysteine residues and pharmaceutical compositions containing the same - Google Patents

Proteins and polypeptides having substituted cysteine residues and pharmaceutical compositions containing the same

Info

Publication number
IL97932A
IL97932A IL97932A IL9793291A IL97932A IL 97932 A IL97932 A IL 97932A IL 97932 A IL97932 A IL 97932A IL 9793291 A IL9793291 A IL 9793291A IL 97932 A IL97932 A IL 97932A
Authority
IL
Israel
Prior art keywords
protein
leu
polypeptide
integer
ser
Prior art date
Application number
IL97932A
Other languages
English (en)
Other versions
IL97932A0 (en
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL97932A0 publication Critical patent/IL97932A0/xx
Publication of IL97932A publication Critical patent/IL97932A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL97932A 1990-05-04 1991-04-24 Proteins and polypeptides having substituted cysteine residues and pharmaceutical compositions containing the same IL97932A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51904790A 1990-05-04 1990-05-04

Publications (2)

Publication Number Publication Date
IL97932A0 IL97932A0 (en) 1992-06-21
IL97932A true IL97932A (en) 1998-02-22

Family

ID=24066559

Family Applications (1)

Application Number Title Priority Date Filing Date
IL97932A IL97932A (en) 1990-05-04 1991-04-24 Proteins and polypeptides having substituted cysteine residues and pharmaceutical compositions containing the same

Country Status (17)

Country Link
EP (1) EP0458064B1 (de)
JP (1) JPH069696A (de)
KR (1) KR100213455B1 (de)
AT (1) ATE163431T1 (de)
AU (1) AU639324B2 (de)
CA (1) CA2041742A1 (de)
DE (1) DE69128944T2 (de)
DK (1) DK0458064T3 (de)
ES (1) ES2113354T3 (de)
FI (1) FI912144A7 (de)
GR (1) GR3026436T3 (de)
IE (1) IE911511A1 (de)
IL (1) IL97932A (de)
NO (1) NO911752L (de)
NZ (1) NZ237959A (de)
PT (1) PT97539B (de)
ZA (1) ZA913359B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
GB9100381D0 (en) * 1991-01-09 1991-02-20 Erba Carlo Spa Human bfgf derivatives,their analogs and process for their production
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
CA2124672A1 (en) * 1991-12-10 1993-06-24 Tse W. Chang Cytokines with an upaired cysteine residue and conjugates thereof
EP0679095A1 (de) * 1992-11-25 1995-11-02 Amgen Boulder Inc. Modifizierte insulinartigen wachtstumfaktor
EP0622394A1 (de) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7270809B2 (en) 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
CN1269805A (zh) 1997-07-14 2000-10-11 博尔德生物技术公司 生长激素和相关蛋白的衍生物
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
AU2008202371B2 (en) * 1999-01-14 2012-08-02 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002055532A2 (en) * 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
EA008505B1 (ru) * 2001-11-20 2007-06-29 Фармация Корпорейшн Конъюгаты химически модифицированного гормона роста человека
CN102319437B (zh) 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
US7524813B2 (en) 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
WO2005035553A2 (en) * 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
US8329866B2 (en) 2005-10-03 2012-12-11 Bolder Biotechnology, Inc. Long acting VEGF inhibitors and methods of use
US8617531B2 (en) 2006-12-14 2013-12-31 Bolder Biotechnology, Inc. Methods of making proteins and peptides containing a single free cysteine
RU2605627C2 (ru) 2010-01-22 2016-12-27 Ново Нордиск Хелс Кеа Аг Гормоны роста с пролонгированной эффективностью in vivo
EP2981282B1 (de) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Wachstumshormonverbindungsformulierung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
ES2154627T3 (es) * 1988-08-24 2001-04-16 American Cyanamid Co Estabilizacion de somatotropinas mediante la modificacion de restos de cisteina utilizando mutagenesis de localizacion dirigida o derivatizacion quimica.
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof

Also Published As

Publication number Publication date
ES2113354T3 (es) 1998-05-01
KR910020032A (ko) 1991-12-19
DE69128944D1 (de) 1998-04-02
JPH069696A (ja) 1994-01-18
AU639324B2 (en) 1993-07-22
IE911511A1 (en) 1991-11-06
DE69128944T2 (de) 1998-06-25
ATE163431T1 (de) 1998-03-15
CA2041742A1 (en) 1991-11-05
NZ237959A (en) 1994-05-26
NO911752D0 (no) 1991-05-03
EP0458064A3 (en) 1992-06-17
PT97539B (pt) 1998-08-31
EP0458064A2 (de) 1991-11-27
AU7607591A (en) 1991-11-07
FI912144L (fi) 1991-11-05
DK0458064T3 (da) 1998-04-27
ZA913359B (en) 1992-03-25
PT97539A (pt) 1992-02-28
FI912144A7 (fi) 1991-11-05
IL97932A0 (en) 1992-06-21
FI912144A0 (fi) 1991-05-03
GR3026436T3 (en) 1998-06-30
EP0458064B1 (de) 1998-02-25
KR100213455B1 (ko) 1999-08-02
NO911752L (no) 1991-11-05

Similar Documents

Publication Publication Date Title
EP0458064B1 (de) Stabilisierung von Somatotropin durch Modifizierung von Cysteinsresten
US5951972A (en) Stabilization of somatotropins and other proteins by modification of cysteine residues
EP0355460B1 (de) Stabilisierung von Somatotropinen durch Modifikation von Cystein-Resten durch orts-spezifische Mutagenese oder chemische Derivatisierung
JP5431874B2 (ja) ポリエチレングリコール−ｇｒｆ結合体の部位特異的調製方法
AU714439B2 (en) Amylin agonist peptides and uses therefor
IL97232A (en) Polypropylene polymer flame retardants and a process for their preparation
JP2003525864A (ja) 共有結合で架橋されたインスリンダイマー
JP2002528562A (ja) 長さのばらつきが小さいポリアミド連鎖、その連鎖の製造方法およびその連鎖とタンパク質の複合体
CA2467731A1 (en) Chemically-modified human growth hormone conjugates
CA1268898A (en) Growth hormone-releasing peptides and method of treating mammals therewith
IE60870B1 (en) Tripeptides and pharmaceutical compositions containing them
CA2507616A1 (en) Highly stable pacap/vip-derived peptides
JPH09502175A (ja) 免疫およびｃｎｓ療法に有用な新規トリペプチド
KR20080041661A (ko) 생체적합성 폴리머와 컨쥬게이트된 인간 성장 호르몬
JPH05279388A (ja) 超活性ｇｒｆ類縁体
US20060134736A1 (en) Human growth hormone conjugated with biocompatible polymer
KR0130969B1 (ko) 동물의 재조합 소마토트로핀과 그의 응집을 막는 방법 및 그를 포함하는 제약학적 조성물
JPS6330499A (ja) オピオイドペプチド・ポリペプチド複合体
Pató et al. Synthesis of New Poly (N-Vinyl Pyrrolidone-Co-Maleic Acid) Peptide Hormone Conjugates with Anticancer Activity
HU201566B (en) Process for producing new analoguse of activatin factor of human growth hormon and pharmaceutical and veterinair compositions containing them
JPWO1999057147A1 (ja) ヒトトロンボポエチン変異体

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees